Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02482168 · ClinicalTrials.gov registry record · Phase 1
Study of the CD40 Agonistic Monoclonal Antibody APX005M
A Phase 1 study of Cancer and Melanoma, sponsored by Apexigen America.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
- 3
- Study locations
NCT02482168 is a Phase 1 study of Cancer and Melanoma that has completed, run by Apexigen America. The registered enrollment target is 43 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02482168, a Phase 1 study of Cancer and Melanoma, has completed, sponsored by Apexigen America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is a phase 1 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M in adults with solid tumors. Study is intended to establish the maximum tolerated dose and the overall safety and tolerability of APX005M in 3 different administration schedules.
Conditions Studied
Interventions
- DRUG APX005M
Study Locations (3)
California
- City of Hope - Duarte
Ohio
- Case Western Reserve University - Cleveland
Pennsylvania
- Abramson Cancer Center of The University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2015-05 |
| Est. Completion | 2018-06-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02482168
The ClinicalTrials.gov registry entry for NCT02482168 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Apexigen America, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which APX005M is the first listed.
NCT02482168 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02482168 about?
NCT02482168 is a clinical study titled "Study of the CD40 Agonistic Monoclonal Antibody APX005M". This study is a phase 1 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M in adults with solid tumors. Study is intended to establish the maximum tolerated dose and the overall safety and tolerability of APX005M in 3 different administration schedules.
What is the current status of trial NCT02482168?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2015-05. Estimated completion is 2018-06-19.
What conditions does trial NCT02482168 study?
This clinical trial studies the following conditions: Cancer, Melanoma, Head and Neck Cancer, Urothelial Carcinoma, NSCLC.
What interventions are being tested in trial NCT02482168?
The interventions under investigation include: APX005M (DRUG).
Who is sponsoring clinical trial NCT02482168?
This trial is sponsored by Apexigen America, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02482168 being conducted?
This trial has 3 study locations across California, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.